199 related articles for article (PubMed ID: 24819397)
21. Crystal structure of a binary complex between human GCN5 histone acetyltransferase domain and acetyl coenzyme A.
Schuetz A; Bernstein G; Dong A; Antoshenko T; Wu H; Loppnau P; Bochkarev A; Plotnikov AN
Proteins; 2007 Jul; 68(1):403-7. PubMed ID: 17410582
[No Abstract] [Full Text] [Related]
22. The HTLV-1-encoded protein HBZ directly inhibits the acetyl transferase activity of p300/CBP.
Wurm T; Wright DG; Polakowski N; Mesnard JM; Lemasson I
Nucleic Acids Res; 2012 Jul; 40(13):5910-25. PubMed ID: 22434882
[TBL] [Abstract][Full Text] [Related]
23. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
24. Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator.
Tanner KG; Trievel RC; Kuo MH; Howard RM; Berger SL; Allis CD; Marmorstein R; Denu JM
J Biol Chem; 1999 Jun; 274(26):18157-60. PubMed ID: 10373413
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
[TBL] [Abstract][Full Text] [Related]
26. Kinetic mechanism of human histone acetyltransferase P/CAF.
Tanner KG; Langer MR; Denu JM
Biochemistry; 2000 Oct; 39(39):11961-9. PubMed ID: 11009610
[TBL] [Abstract][Full Text] [Related]
27. Catalysis by protein acetyltransferase Gcn5.
Albaugh BN; Denu JM
Biochim Biophys Acta Gene Regul Mech; 2021 Feb; 1864(2):194627. PubMed ID: 32841743
[TBL] [Abstract][Full Text] [Related]
28. Current development of CBP/p300 inhibitors in the last decade.
He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
[TBL] [Abstract][Full Text] [Related]
29. Solution structure of the catalytic domain of GCN5 histone acetyltransferase bound to coenzyme A.
Lin Y; Fletcher CM; Zhou J; Allis CD; Wagner G
Nature; 1999 Jul; 400(6739):86-9. PubMed ID: 10403255
[TBL] [Abstract][Full Text] [Related]
30. 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site.
Ghizzoni M; Wu J; Gao T; Haisma HJ; Dekker FJ; George Zheng Y
Eur J Med Chem; 2012 Jan; 47(1):337-44. PubMed ID: 22100137
[TBL] [Abstract][Full Text] [Related]
31. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
[TBL] [Abstract][Full Text] [Related]
32. Crystallographic analysis of the reaction pathway of Zoogloea ramigera biosynthetic thiolase.
Modis Y; Wierenga RK
J Mol Biol; 2000 Apr; 297(5):1171-82. PubMed ID: 10764581
[TBL] [Abstract][Full Text] [Related]
33. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.
Zucconi BE; Luef B; Xu W; Henry RA; Nodelman IM; Bowman GD; Andrews AJ; Cole PA
Biochemistry; 2016 Jul; 55(27):3727-34. PubMed ID: 27332697
[TBL] [Abstract][Full Text] [Related]
34. Multiple roles for acetylation in the interaction of p300 HAT with ATF-2.
Karanam B; Wang L; Wang D; Liu X; Marmorstein R; Cotter R; Cole PA
Biochemistry; 2007 Jul; 46(28):8207-16. PubMed ID: 17590016
[TBL] [Abstract][Full Text] [Related]
35. Tumor Suppressor p53-Mediated Structural Reorganization of the Transcriptional Coactivator p300.
Ghosh R; Kaypee S; Shasmal M; Kundu TK; Roy S; Sengupta J
Biochemistry; 2019 Aug; 58(32):3434-3443. PubMed ID: 31314496
[TBL] [Abstract][Full Text] [Related]
36. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300.
Zeng L; Zhang Q; Gerona-Navarro G; Moshkina N; Zhou MM
Structure; 2008 Apr; 16(4):643-52. PubMed ID: 18400184
[TBL] [Abstract][Full Text] [Related]
37. Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition.
Bishop TR; Subramanian C; Bilotta EM; Garnar-Wortzel L; Ramos AR; Zhang Y; Asiaban JN; Ott CJ; Rock CO; Erb MA
Nat Chem Biol; 2023 Oct; 19(10):1215-1222. PubMed ID: 37127754
[TBL] [Abstract][Full Text] [Related]
38. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.
Shirakawa K; Wang L; Man N; Maksimoska J; Sorum AW; Lim HW; Lee IS; Shimazu T; Newman JC; Schröder S; Ott M; Marmorstein R; Meier J; Nimer S; Verdin E
Elife; 2016 May; 5():. PubMed ID: 27244239
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
40. Transcription factor dimerization activates the p300 acetyltransferase.
Ortega E; Rengachari S; Ibrahim Z; Hoghoughi N; Gaucher J; Holehouse AS; Khochbin S; Panne D
Nature; 2018 Oct; 562(7728):538-544. PubMed ID: 30323286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
